GW Pharmaceuticals Plc ADS (GWPH)

[Cosa]

I hope we can deliver a beat tomorrow morning or I could be on my way to -30%.

[XWAVXALMIMAN]

News today on small Israeli cannabis company

https://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-receives-intention-to-grant-a-european-patent-notice-for-its-system-and-method-for-high-throughput-screening-of-cancer-cells-patent-application-301160664.html

[Taurus69]

$gwph $95.0 v -2.04 (-2.10%)
Volume: 260,083 @10/23/20 5:59:48 PM EDT

[mc73]

Lol. Want to buy shares in a legit company on NASDAQ or a stinky penny stock drowning in debt? Lol!!

[Cosa]

I am not reading that either lol. That is a ridiculous comparison.

[john1311]

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020

https://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-plc-report-financial-results-and-6

[john1311]

Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community

CARLSBAD, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Greenwich Biosciences, Inc., the US leader in the field of cannabinoid prescription medicines and subsidiary of GW Pharmaceuticals plc (Nasdaq: GWPH), today announced the launch of unspoken symphony, a web-based, image-recognition technology that gives individuals with epilepsy who struggle to express themselves verbally a new way to communicate and connect like never before by translating artwork into a melody. Many people living with epilepsy may experience developmental delays or cognitive impairment in addition to seizures, making it challenging to verbalize or connect with others. This is particularly common in seizure conditions such as Lennox-Gastaut syndrome (LGS), Dravet syndrome and tuberous sclerosis complex (TSC).i,ii Often, individuals with limited verbal ability turn to art and/or music therapy as a way to express themselves. unspoken symphony offers a unique way to bridge the two.

https://ir.gwpharm.com/news-releases/news-release-details/greenwich-biosciences-inc-subsidiary-gw-pharmaceuticals-plc

[mc73]

Not even close. I dont need to read...GWPH all the way especially at these prices

[BottomBounce]

Better Buy: Medical Marijuana vs. GW Pharmaceuticals
$GWPH vs $MJNA

https://www.fool.com/investing/2019/04/03/better-buy-medical-marijuana-vs-gw-pharmaceuticals.aspx

[Kim1111]

I know I just don’t get it! Never been down so much so fast in my life on this trade. Riding it out w optimistic expectations

[mc73]

I am watching the price in disbelief. I will continue to watch and will try to buy "at the bottom" but honestly they just increased revenue with Australia, we just don't know how many millions per Q that will be.

$100 is a great buy, anything lower is bonus buy imo

[Cosa]

-20.04%, I would use the hand on face emoji if i could lol. I guess I will buy some shares today.

[Cosa]

This is great news, extending it's reach and adding revenue.

[Taurus69]

$gwph $100.0001 ^ 1.5001 (1.52%)
Volume: 160,029 @09/25/20 7:42:40 PM EDT

[john1311]

GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

This represents the third successful regulatory approval globally for GW’s plant-derived cannabis-based medicine

LONDON, Sept. 23, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the Australian Therapeutic Goods Administration (TGA) has approved EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age and older.

This represents GW’s cannabis-based medicine’s third global regulatory approval, following US Food and Drug Administration (FDA) approval in 2018 and European Commission (EC) approval in 2019. GW has partnered with Chiesi Australia to make this medicine available in Australia, and the Company will now work alongside its partner and Australia’s Pharmaceutical Benefits Advisory Committee (PBAC) to secure reimbursement for the medicine through a listing on the Pharmaceutical Benefits Scheme (PBS).

“GW was founded over two decades ago with a mission to bring cannabis-based medicines to patients with an unmet medical need. We are proud to now be able to bring GW’s cannabidiol to patients in Australia following this approval and our partnership with Chiesi Australia,” said Chris Tovey, GW’s Chief Operating Officer. “This marks our third global regulatory approval and is another important step for GW and the patients we are here to support. The TGA approval is further proof that cannabis-based medicines can successfully go through extensive randomised placebo-controlled trials and a rigorous evaluation process to reach patients who need them.”

“We are delighted to announce the TGA registration of EPIDYOLEX®, an important step forward for the management of LGS and Dravet syndrome. We are working closely with the Department of Health to achieve greater access to this medicine as soon as possible,” said Chris Rossidis, General Manager, Chiesi Australia.

The approval of GW’s cannabidiol is based on results from four randomised, controlled Phase 3 trials. These studies incorporate data from more than 714 patients with either LGS or Dravet syndrome, two rare forms of epilepsy with high morbidity and mortality rates, which place a significant burden on families and caregivers. Many patients with LGS or Dravet syndrome have multiple seizures per day, which puts them at ongoing risk of falls and injury. Despite current anti-epileptic drug treatment, both of these severe forms of epilepsy remain highly treatment-resistant.1,2,3

https://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-receives-australian-therapeutic-goods

[Cosa]

Good entry point, I think you will do well. GL

[Kim1111]

So much for that excitement!

[Kim1111]

I’ve been following GWPH for years and never could afford to get in until now. I’m very excited to see their progress! GLTA

[john1311]

The Financial Times today 15th Sept 2020:

Share price forecast
The 16 analysts offering 12 month price targets for GW Pharmaceuticals PLC- ADR have a median target of 186.50, with a high estimate of 275.00 and a low estimate of 136.00. The median estimate represents a 74.48% increase from the last price of 106.89.

[Taurus69]

$gwph $100.02 v -3.0 (-2.91%)
Volume: 398,206 @09/10/20 7:53:51 PM EDT

[MomsSpaghetti]

Could be a good buy now... Legislation changing hard on Cannabis. Next wave coming

[MomsSpaghetti]

Could be a good buy now... Legislation changing hard on Cannabis. Next wave coming

[Taurus69]

$gwph $109.31 v -0.15 (-0.14%)
Volume: 165,418 @08/21/20 6:07:24 PM EDT

[rinoo]

Soon at 110$

[TFMG]

$GWPH | #GWPharma Possible Reversal trade



Potential long above the 7ma @ $110
Upside target $116 short term with the 200ma as resistance.
Indicators have began to bottom and attempting to reverse.

[Taurus69]

$gwph $109.87 ? 0.0 (0.00%)
Volume: 5 @08/18/20 7:03:25 AM EDT

[Stockshound]

I heard gwph talk once again.. lets see if it makes mainstream?

[rinoo]

Good reports for CGC - the stock is likely to return today around $ 115

[rinoo]

Tomorrow the CGC reports for Q2 - if they are good they can be a catalyst for the entire cannabis sector.

[Tanis2476]

3-4 weeks, I wouldn’t worry about it

[rinoo]

Probably not more than a month

[Cosa]

Crap, now my shares are stuck at $120. Going to have to wait months for it to come back lol

[rinoo]

Looks not good - i will wait until Monday after CGC report

[rinoo]

You think $ 116 is a good price to buy this stock ? - I have positions in other cannabis stocks but I've always avoided it because it's expensive - although it's true it has this approval for a cannabis-based drug.

[Tanis2476]

Good call!

[Cosa]

Wow -15% afterhours. I just bought back in at $120.25

[john1311]

excellent news, thanks Tanis2476.

[conesa]

Absolutely put your money in right now

[mc73]

Does anyone expect a small run with this news?

[Tanis2476]

They got it!


FDA Approves New Indication for Drug Containing an Active Ingredient Derived from Cannabis to Treat Seizures in Rare Genetic Disease
U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)
NEWS PROVIDED BY
U.S. Food and Drug Administration
Jul 31, 2020, 21:06 ET
SILVER SPRING, Md., July 31, 2020 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Epidiolex (cannabidiol) [CBD] oral solution for the treatment of seizures associated with tuberous sclerosis complex (TSC) in patients one year of age and older. Epidiolex was previously approved for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS). This is the only FDA-approved drug that contains a purified drug substance derived from cannabis. It is also the second FDA approval of a drug for the treatment of seizures associated with TSC.

[conesa]

Is the news coming out after market close? And where could we read it first?

[Taurus69]

$gwph $126.71 ^ 0.45 (0.36%)
Volume: 204,106 @07/29/20 7:03:47 PM EDT

[Taurus69]

$gwph $126.26 v -2.49 (-1.93%)
Volume: 183,689 @07/28/20 6:04:17 PM EDT

[mc73]

And it's really a pharma company using CBD as their drug - might start a position Monday

[Taurus69]

$gwph $126.17 v -2.83 (-2.19%)
Volume: 362,028 @07/24/20 6:44:18 PM EDT

[Taurus69]

$gwph $129.0 v -4.94 (-3.69%)
Volume: 299,293 @07/23/20 7:33:43 PM EDT

[fung_derf]

[Tanis2476]

Thoughts from anyone on the articles going around from researchers stating research needs to be done immediately on CBD effects on treating lungs of COVID patients? Several articles making the rounds over last two weeks and I would guess has had impact on the SP.

[Taurus69]

$gwph $137.13 ^ 1.75 (1.29%)
Volume: 241,890 @07/17/20 5:59:02 PM EDT

[fung_derf]

Sounds more like a sex toy.

Sativex continues increasing its penetration in the German market